Tremor is the most common movement disorder with an estimated 41 million Essential Tremor (ET) patients and 10 million Parkinson Disease (PD) worldwide. Our research lab is currently conducting the largest and longest comprehensive tremor study in the world. The involuntary rhythmic movements of tremor in limbs are caused by the synchronized or alternating contraction of agonist-antagonist muscle groups. PD patients often exhibit postural and kinetic tremor in addition to their expected rest tremor, while ET patients predominantly show resting tremor in later disease stages. Further ET patients exhibit tremors on both sides earlier on. The use of botulinum neurotoxin type A (BoNT A) for the treatment of focal dystonia is well established, however its use for the treatment of upper limb tremor is hindered by difficulties in muscle selection for injection by visual inspection alone. Our research has digitized the assessment and fast-tracked tremor treatment by eliminating the barriers that prevent patients from getting adequate treatment.